Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Think Twice before Issuing Long-Term Prescriptions for Supply-Curbed Generics: JMA
October 5, 2021
- MEJ Study Group Calls for Electronic Medical Chart Reform to Expedite Clinical Trials, New Drug Development
October 4, 2021
- FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
- FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
- Generic Use Rate Slips to 79.8% in April-June: JGA
September 30, 2021
- Chuikyo Payer Rep Wants to Cut into Cost-Based Method, Adjustment Rate, Off-Year Revision in FY2022 Reform, Eyes Special Rules for Aducanumab
September 27, 2021
- Teva Takeda CEO Named Chairman of Established Drugs’ Group
September 24, 2021
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- FPMAJ Conducting Survey on Efforts for Stable Supplies of Ethical Drugs; Response Deadline Sept. 30
September 21, 2021
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
- Bills Exceeding 10 Million Yen Monthly Increase 60%, SMA Dominates Top 7: Payer Report
September 17, 2021
- JMA Think Tank Sees Problems with Proposals to Revise Health Coverage for Drugs
September 15, 2021
- Generic Trade Group Sets Out 4 Pledges on Quality, Stable Supply
September 15, 2021
- FPMAJ Vows to Work towards Achieving New Pharma Industry Vision
September 15, 2021
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- JMA Think Tank Urges Discussions to Prep for Aducanumab Approval
September 8, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- EFPIA Japan Issues Viewpoint on Cost Effectiveness Assessment System
August 31, 2021
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…